Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
Ginkgo Bioworks, a leading horizontal platform for cell programming, announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.
Regeneron Pharmaceuticals shared positive results from the company’s Phase III trial of a candidate drug for children with homozygous familial hypercholesterolemia (HoFH), a rare, life-threatening condition characterized by elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD.
If you flip through history, you’ll realize that our fundamental healthcare needs haven’t changed since the year 1885. We still seek rest when we’re ill, feel pain when we overexert ourselves, and need guidance from experts on our health and wellness. But the tools we have to meet these perennial needs have shifted dramatically since the 19th century, and especially over the past decade, wherein technology has advanced faster than even the greatest Sci-Fi film producers imagined, according to Greater Than One Chief Technology Officer Ken Winell.